CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -456.14M | -451.14M | -568.53M | -581.60M | -488.30M |
| Total Depreciation and Amortization | 18.50M | 18.69M | 19.06M | 19.48M | 18.66M |
| Total Amortization of Deferred Charges | 1.58M | 848.00K | -- | -- | -- |
| Total Other Non-Cash Items | 55.74M | 47.58M | 147.88M | 145.22M | 142.25M |
| Change in Net Operating Assets | 5.68M | 14.44M | 1.63M | 71.88M | 24.89M |
| Cash from Operations | -374.63M | -369.58M | -399.96M | -345.01M | -302.49M |
| Capital Expenditure | -2.08M | -1.74M | -1.21M | -914.00K | -651.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -441.21M | -546.69M | -421.58M | -30.89M | 37.48M |
| Cash from Investing | -443.29M | -548.43M | -422.79M | -31.81M | 36.82M |
| Total Debt Issued | 600.00M | 600.00M | 600.00M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 135.33M | 427.64M | 421.60M | 426.03M | 326.49M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15.37M | -15.37M | -14.25M | -- | -- |
| Cash from Financing | 719.96M | 1.01B | 1.01B | 426.03M | 326.49M |
| Foreign Exchange rate Adjustments | -19.00K | -52.00K | 22.00K | 95.00K | 7.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.98M | 94.21M | 184.61M | 49.30M | 60.83M |